Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

February 12, 2021

Study Completion Date

February 12, 2021

Conditions
Multiple Sclerosis
Interventions
DRUG

BIIB033 (opicinumab)

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (159)

185

Research Site, Roma

1090

Research Site, Brussels

1135

Research Site, Budapest

1145

Research Site, Budapest

1200

Research Site, Brussels

1307

Research Site, Dresden

2143

Research Site, Kistarcsa

2145

Research Site, Westmead

2500

Research Site, Esztergom

3000

Research Site, Leuven

3004

Research Site, Melbourne

3010

Research Site, Bern

3050

Research Site, Parkville

3084

Research Site, Heidelberg

3128

Research Site, Box Hill

3168

Research Site, Clayton

4031

Research Site, Basel

5001

Research Site, Aarau

6903

Research Site, Lugano

7100

Research Site, La Louvière

7623

Research Site, Pécs

8000

Research Site, Bruges

8035

Research Site, Barcelona

8036

Research Site, Barcelona

8091

Research Site, Zurich

8800

Research Site, Roeselare

9000

Research Site, Ghent

10021

Research Site, New York

10117

Research Site, Berlin

11772

Research Site, Patchogue

11794

Research Site, Stony Brook

12110

Research Site, Latham

12808

Research Site, Prague

14004

Research Site, Córdoba

14642

Research Site, Rochester

15213

Research Site, Pittsburgh

16132

Research Site, Genova

17190

Research Site, Salt

19090

Research Site, Willow Grove

20007

Research Site, Washington D.C.

20132

Research Site, Milan

20133

Research Site, Milan

21287

Research Site, Baltimore

25018

Research Site, Montichiari

27607

Research Site, Raleigh

27710

Research Site, Durham

28006

Research Site, Madrid

28222

Research Site, Majadahonda

30029

Research Site, Nîmes

30309

Research Site, Atlanta

31059

Research Site, Toulouse

33076

Research Site, Bordeaux

33351

Research Site, Sunrise

33612

Research Site, Tampa

34295

Research Site, Montpellier

35058

Research Site, Cullman

37134

Research Site, Verona

37922

Research Site, Knoxville

38018

Research Site, Memphis

40225

Research Site, Düsseldorf

40513

Research Site, Lexington

41009

Research Site, Seville

43214

Research Site, Columbus

44093

Research Site, Nantes

44791

Research Site, Bochum

45417

Research Site, Dayton

48149

Research Site, Münster

48334

Research Site, Farmington Hills

48903

Research Site, Barakaldo

50005

Research Site, Hradec Králové

53203

Research Site, Pardubice

54292

Research Site, Trier

55422

Research Site, Minneapolis

56126

Research Site, Pisa

58601

Research Site, Jihlava

59000

Research Site, Lille

60612

Research Site, Chicago

60637

Research Site, Chicago

63003

Research Site, Clermont-Ferrand

63110

Research Site, St Louis

63131

Research Site, St Louis

65691

Research Site, Brno

66212

Research Site, Overland Park

66491

Research Site, Brno

67098

Research Site, Strasbourg

69500

Research Site, Bron

72076

Research Site, Tübingen

73104

Research Site, Oklahoma City

75013

Research Site, Paris

77030

Research Site, Houston

78681

Research Site, Round Rock

79106

Research Site, Freiburg im Breisgau

80054

Research Site, Amiens

80055

Research Site, Napoli

80112

Research Site, Centennial

80131

Research Site, Napoli

80138

Research Site, Napoli

80528

Research Site, Fort Collins

81675

Research Site, Munich

84058

Research Site, Orem

84103

Research Site, Salt Lake City

85234

Research Site, Gilbert

86077

Research Site, Pozzilli

89081

Research Site, Ulm

89106

Research Site, Las Vegas

90015

Research Site, Cefalù

90806

Research Site, Long Beach

92663

Research Site, Newport Beach

92868

Research Site, Orange

94705

Research Site, Berkeley

97225

Research Site, Portland

98122

Research Site, Seattle

98124

Research Site, Messina

98133

Research Site, Seattle

5262000

Research Site, Ramat Gan

06905

Research Site, Stamford

02114

Research Site, Boston

02215

Research Site, Boston

01805

Research Site, Lexington

02481

Research Site, Wellesley

07728

Research Site, Freehold

07666

Research Site, Teaneck

75390-8806

Research Site, Dallas

NS 2305

Research Site, New Lambton Heights

T6G 1Z1

Research Site, Edmonton

V6T 1Z3

Research Site, Vancouver

V8R 1J8

Research Site, Victoria

K1H8L6

Research Site, Ottawa

M5B1W8

Research Site, Toronto

J8Y 1W2

Research Site, Gatineau

J4V2J2

Research Site, Longueuil

H3A 2B4

Research Site, Montreal

H-1204

Research Site, Budapest

6162 AP

Research Site, Geleen

85-795

Research Site, Bydgoszcz

80-803

Research Site, Gdansk

40-571

Research Site, Katowice

40-650

Research Site, Katowice

31-637

Research Site, Krakow

90-324

Research Site, Lodz

20-954

Research Site, Lublin

70-111

Research Site, Szczecin

04-749

Research Site, Warsaw

41-800

Research Site, Zabrze

08907

Research Site, Barcelona

EX2 5DW

Research Site, Exeter

PL6 8DH

Research Site, Plymouth

SE5 9RS

Research Site, London

W6 8RF

Research Site, London

M6 8HD

Research Site, Salford

L9 7LJ

Research Site, Liverpool

NG7 2UH

Research Site, Nottingham

OX3 9DU

Research Site, Oxford

G51 4TF

Research Site, Glasgow

NE1 4LP

Research Site, Newcastle upon Tyne

LS1 3EX

Research Site, Leeds

BN2 5BE

Research Site, Brighton

S10 2JF

Research Site, Sheffield

SA6 6NL

Research Site, Swansea

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03222973 - Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter